stockrow
Saturday 7 November 2026
Export BYSI’s income statement to Excel — free account
BeyondSpring Inc.
BYSI Healthcare Biotechnology
BeyondSpring Inc.’s revenue for fiscal 2022 (year ended December 2022) was $1.4 million.
- EPS
- +50.0%
- Free cash flow
- +35.8%
Quarter to June 2026, against a year earlier
0.61
0.02
−3.17%
Follow BYSI
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | 0 | 1 | 1 | — | — | — | 1 | +174.0% | — | — | — | — | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 100.00 | 100.00 | 100.00 | 100.00 | — | — | 100.00 | +100.0 pt | ||||||
| EBT | (13) | (96) | (57) | (40) | (64) | (65) | (36) | (14) | (9) | (9) | (8) | (4.1%) | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | (35,456.11) | (4,784.46) | (2,673.35) | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | (13) | (96) | (57) | (40) | (64) | (68) | (36) | (22) | (17) | (14) | (23) | +1.4% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.03 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (0.75) | (4.40) | (2.42) | (1.55) | (2.03) | (1.64) | (0.85) | (0.54) | (0.28) | (0.02) | (0.17) | (33.1%) | ||||||
| Cash flow | (0.85) | (1.38) | (1.76) | (1.95) | (1.46) | (1.21) | (0.72) | (0.42) | (0.41) | (0.49) | (0.41) | (6.0%) | ||||||
| Capex | 0.00 | 0.00 | (0.01) | 0.00 | 0.00 | (0.07) | 0.02 | 0.00 | (0.01) | 0.00 | 0.00 | (12.5%) | ||||||
| Free cash flow | (0.86) | (1.38) | (1.77) | (1.95) | (1.46) | (1.28) | (0.70) | (0.42) | (0.42) | (0.49) | (0.41) | (6.0%) | ||||||
| Book value | 0.76 | 1.34 | (0.41) | 1.26 | 2.89 | 0.54 | (0.36) | (0.91) | (0.36) | (0.59) | (0.88) | n/m | ||||||
| Shares, m | 16 | 21 | 23 | 25 | 30 | 39 | 39 | 39 | 40 | 40 | 41 | +10.8% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | 0.00 | 130.85 | 50.55 | 24.84 | — | — | 18.57 | 51.6 | ||||||
| P/B | — | — | — | — | 4.22 | 8.45 | 64.37 | 0.00 | — | — | 0.00 | 19.3 | ||||||
| EV/Sales | — | — | — | — | 0.00 | 78.92 | 13.74 | 8.49 | — | — | 15.37 | 25.3 | ||||||
| EV/FCF | — | — | — | — | (5.92) | (2.13) | (0.37) | (0.23) | — | — | (1.24) | (2.2) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (14) | (29) | (40) | (48) | (44) | (47) | (28) | (16) | (16) | (20) | (17) | +4.2% | |||||
| Capex | 0 | 0 | 0 | 0 | 0 | (3) | 1 | 0 | 0 | 0 | 0 | (2.7%) | ||||||
| Free cash flow | (14) | (29) | (40) | (48) | (44) | (50) | (27) | (17) | (17) | (20) | (17) | +4.1% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 12 | 28 | (11) | 31 | 100 | 60 | 31 | 10 | 18 | 7 | (4) | (5.4%) | |||||
| Net debt | (12) | (31) | (4) | (34) | (107) | (71) | (37) | (15) | (3) | (13) | (7) | +0.8% | ||||||
| Shareholders’ equity | 12 | 28 | (9) | 31 | 87 | 21 | (14) | (35) | (14) | (24) | (36) | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (92.82) | (384.46) | (275.09) | (147.56) | (75.46) | (64.60) | (52.05) | (59.20) | (37.63) | (3.34) | (29.29) | +89.5 pt | |||||
| ROIC | (1,263.07) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | +1,263.1 pt | ||||||
| ROE | (109.40) | (455.00) | (588.28) | (350.22) | (103.56) | (119.35) | (972.79) | 85.10 | 44.83 | 5.26 | 24.96 | +114.7 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 25 | 38 | 52 | 61 | 91 | 103 | 73 | 36 | 40 | 44 | — | +6.5% | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2022 · latest quarter Dec 2021 · fundamentals updated 26 Oct 2026
BeyondSpring Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ALGS Aligos Therapeutics, Inc. | $28.2M | — (loss-making) | — (loss-making) | +287.18% (above 0%: growing) | n/m | +105.91% (above 0%: growing) | 100.00% | (762.98%) | Compare |
| MGX Metagenomi Therapeutics, Inc. | $27.6M | — (loss-making) | — (loss-making) | −103.02% (below 0%: shrinking) | n/m | +7.98% (above 0%: growing) | 100.00% | 11,195.72% | Compare |
| PLRZ Polyrizon Ltd. | $27.5M | — | — | — | — | −744.51% (below 0%: shrinking) | — | — | Compare |
| ACET Adicet Bio, Inc. | $27.3M | — (loss-making) | — (loss-making) | +727.73% (above 0%: growing) | n/m | +24.94% (above 0%: growing) | 0.00% | 0.00% | Compare |
| BYSI BeyondSpring Inc. | $26.0M | — (loss-making) | — (loss-making) | +87.78% (above 0%: growing) | n/m | +35.78% (above 0%: growing) | 100.00% | 0.00% | |
| ABVC ABVC BioPharma, Inc. | $25.9M | — (loss-making) | — (loss-making) | +66,233.33% (above 0%: growing) | n/m | +72.66% (above 0%: growing) | 100.00% | 0.00% | Compare |
| RNAZ TransCode Therapeutics Inc. | $25.6M | — (loss-making) | — | — | n/m | −28.79% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| AARD Aardvark Therapeutics, Inc. | $24.3M | — (loss-making) | — | — | n/m | −77.14% (below 0%: shrinking) | — | 0.00% | Compare |
| CVM Cel-Sci Corporation | $24.1M | — (loss-making) | — (loss-making) | −62.66% (below 0%: shrinking) | n/m | −2.33% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $26.6M | — | — | +287.18% | — | +2.82% | 50.00% | 0.00% |